TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history:initial experience in seven cases
10.3969/j.issn.1008-794X.2014.09.016
- VernacularTitle:TACE治疗既往有肝功能衰竭史肝癌患者七例
- Author:
Boshuai YANG
;
Yuxin SHI
;
Min YUAN
;
Jiefei WANG
;
Su ZHOU
;
Junfeng WANG
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
hepatic failure;
transcatheter arterial chemoembolization
- From:
Journal of Interventional Radiology
2014;(9):805-808
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the safety and efficacy of transcatheter arterial chemoembolization (TACE) in treating patients with inoperable hepatocellular carcinoma (HCC) who has a history of hepatic failure. Methods A total of 7 HCC patients who had a history of hepatic failure (study group) were enrolled in this study. TACE was carried out in all these 7 patients. Other 51 patients who had no liver failure history were used as the control group. All the patients were followed up for at least six months. The postoperative adverse events, changes of liver function and the prognosis were recorded, and the results were compared between the two groups. Results In the study group, neither treatment-related death nor severe adverse events occurred. No significant difference in the occurrence of mild adverse events existed between the two groups. After TACE the liver functions, including alanine aminotransferase, total bilirubin, prolonged prothrombin time, albumin, etc. in the study group were significantly worse than those in the control group,groups. Conclusion For patients with inoperable hepatocellular carcinoma who has a history of hepatic failure, TACE is a safe and effective treatment.
